Avidity Biosciences, Inc.

Overview

• IndustryPharmaceutical Preparations¹
• HeadquartersDE¹
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Avidity Biosciences, Inc. sits at the top of its group. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Avidity Biosciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

We currently lease approximately 54,597 square feet of office and laboratory space in San Diego, California, under a lease that expires in 2026, with the option to extend the term of the lease for an additional five years. In April 2024, we entered into a sublease agreement, or the Sublease, to rent 105,000 square feet for office and laboratory space for the Company’s corporate headquarters. The Sublease commenced in August 2025, with a term of 9 years, 9 months. In March 2025, we also exercised the option to rent an additional 80,000 square feet in an adjacent available building under an amended sublease agreement, or the Amended Sublease, with Turning Point Therapeutics, Inc. The term of the Amended Sublease is approximately 9 years, 1 month with payments expected to begin in April 2026. We believe that our current and expected future facilities are adequate to meet our needs and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.

Item 2 of the 10-K filed Feb 23, 2026.¹¹

Leadership

Who has led Avidity Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerSarah Boyce Jun 11, 2020 to now¹²
• PresidentSarah Boyce Jun 11, 2020 to now¹²
• Chief financial officerMichael F. Maclean Jun 11, 2020 to now¹³
• Chief operating officerJoseph Baroldi Jun 11, 2020 to Feb 4, 2021¹⁴

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerW. Michael Flanagan named Mar 19, 2024³⁶

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• Atrium Therapeutics, Inc. Delaware²
• Avidity Biosciences Ireland Limited Republic of Ireland²

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

1. Feb 27, 20268-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer³⁷
2. Feb 26, 20268-K Shareholder vote³⁸
3. Feb 23, 20268-K Other events³⁹
4. Feb 3, 20268-K Regulation FD disclosure; Other events⁴⁰
5. Dec 18, 20258-K Executive or director change; Other events⁴¹
6. Nov 10, 20258-K Results of operations⁴²
7. Oct 27, 20258-K Entered a material agreement; Regulation FD disclosure⁴³
8. Oct 14, 20258-K Other events⁴⁴
9. Sep 12, 20258-K Other events⁴⁵
10. Sep 10, 20258-K Executive or director change; Regulation FD disclosure; Other events⁴⁶
11. Aug 7, 20258-K Entered a material agreement; Results of operations⁴⁷
12. Jul 23, 20258-K Other events⁴⁸
13. Jun 11, 2020New chief executive Sarah Boyce becomes CEO¹²

Calendar

When it reported results

1. Nov 10, 2025Reported quarterly or annual results⁴²
2. Aug 7, 2025Reported quarterly or annual results⁴⁷
3. May 8, 2025Reported quarterly or annual results⁴⁹
4. Feb 27, 2025Reported quarterly or annual results⁵⁰
5. Nov 7, 2024Reported quarterly or annual results⁵¹
6. Aug 9, 2024Reported quarterly or annual results⁵²
7. May 9, 2024Reported quarterly or annual results⁵³
8. Feb 28, 2024Reported quarterly or annual results⁵⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

435 filings to the SEC since October 2021: 5 annual reports, 13 quarterly reports, 64 major events, 198 insider forms, 53 large holders, 1 private raises, 101 other. The latest 20:

1. May 15, 2026SCHEDULE 13G/A EDGAR
2. Mar 9, 202615-12G EDGAR
3. Feb 27, 20264 EDGAR
4. Feb 27, 20264 EDGAR
5. Feb 27, 20264 EDGAR
6. Feb 27, 20264 EDGAR
7. Feb 27, 20264 EDGAR
8. Feb 27, 20264 EDGAR
9. Feb 27, 20264 EDGAR
10. Feb 27, 20264 EDGAR
11. Feb 27, 20264 EDGAR
12. Feb 27, 20264 EDGAR
13. Feb 27, 20264 EDGAR
14. Feb 27, 20264 EDGAR
15. Feb 27, 20264 EDGAR
16. Feb 27, 20264 EDGAR
17. Feb 27, 20264 EDGAR
18. Feb 27, 20264 EDGAR
19. Feb 27, 20264 EDGAR
20. Feb 27, 2026POSASR EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

122 open-market trades by officers, directors and large owners since October 2021: 0 buys and 122 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 6 filings Dec 30, 2022 to May 15, 2026⁵⁵
• Avoro Capital Advisors LLCSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Feb 17, 2026⁵⁶
• Janus Henderson Group Ltd.SCHEDULE 13G/A, 6 filings Feb 14, 2025 to Feb 17, 2026⁵⁷
• PRICE T ROWE ASSOCIATES INC /MD/SCHEDULE 13G/A, 8 filings Feb 14, 2022 to Feb 17, 2026⁵⁸
• Wellington Management CompanySCHEDULE 13G/A, 3 filings Nov 8, 2024 to Feb 10, 2026⁵⁹
• FMR LLCSCHEDULE 13G/A, 7 filings Feb 9, 2022 to Nov 7, 2025⁶⁰
• VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 9, 2023 to Oct 30, 2025⁶¹
• RTW INVESTMENTS, LPSCHEDULE 13D/A, 5 filings Feb 2, 2023 to Oct 29, 2025⁶²
• BlackRockSCHEDULE 13G/A, 1 filing Oct 17, 2025⁶³
• Cowen Financial Products LLCSC 13G/A, 4 filings Aug 18, 2022 to Nov 13, 2024⁶⁴
• State Street CorporationSC 13G/A, 2 filings Feb 3, 2023 to Jan 23, 2024⁶⁵
• EcoR1 Capital, LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 2023⁶⁶
• Cormorant Asset Management, LPSC 13G, 2 filings Feb 14, 2022 to Dec 27, 2022⁶⁷

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Mar 4, 2024Raised $400.2 million in a private offering of equity Form D: 45 investors so far Form D

SEC filer profile

How Avidity Biosciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARAvidity Biosciences, Inc.¹
• CIK0001599901
• Employer ID (EIN)46-1336960¹¹
• Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company¹¹
• Incorporated inDelaware¹¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address3020 Callan Road, San Diego, CA 92121¹
• Phone858-401-7900¹
• Shares outstanding155,149,646 shares as of Feb 13, 2026¹¹
• Public float$3.4B as of Jun 30, 2025¹¹
• AuditorDeloitte & Touche LLP, San Diego, California PCAOB ID 34; it also attests to the company’s internal control over financial reporting¹¹
• On EDGAR sinceFeb 18, 2014¹
• Filings558 in all: 4 (219), 8-K (83), 144 (43), SC 13G/A (30), 3 (26), DEFA14A (20), SCHEDULE 13G/A (18), 10-Q (17)¹
  All 41 form types

  SC 13G (16), 424B5 (12), DFAN14A (7), 10-K (6), S-8 (6), S-8 POS (6), DEF 14A (5), D (4), S-3ASR (4), SC 13D/A (4), ARS (3), CORRESP (3), POSASR (3), S-1/A (3), PRER14A (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), D/A (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), EFFECT (1), PREM14A (1), S-1 (1), S-1MEF (1), SC 13D (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1), UPLOAD (1)

• Latest filingsAnnual report (10-K) Feb 23, 2026
  Quarterly report (10-Q) Nov 10, 2025
  Proxy statement (DEF 14A) Apr 29, 2025
  Latest 8-K (8-K) Feb 27, 2026

Securities registered for trading

From the cover page of the 10-K filed Feb 23, 2026 (Section 12(b) of the Exchange Act).¹¹

Risk factors and legal proceedings

The risks Avidity Biosciences, Inc. names in Item 1A of its 10-K filed Feb 23, 2026: 75 risks under these headings, as written.¹¹

• Risks Related to Our Pending Acquisition by Novartis
• We may not complete the pending transaction with Novartis within the timeframe we anticipate, or at all, which could have an adverse effect on our business, financial results, and/or operations.
• The pendency of the Merger and Distribution could adversely affect our business, financial results and/or operations.
• While the Merger Agreement is in effect, we are subject to restrictions on our business activities.
• In certain instances, the Merger Agreement requires us to pay a termination fee to Novartis, which could require us to use available cash that would have otherwise been available for general corporate purposes.
• We have incurred, and will continue to incur, direct and indirect costs as a result of the pending transaction with Novartis.
• Litigation has arisen in connection with the Merger or the Distribution, which could be costly and divert management’s attention and otherwise materially harm our business.
• The Merger Agreement contains provisions that could discourage a potential competing acquirer of our company or could result in any competing proposal being at a lower price than it might otherwise be.
• The value of SpinCo Common Stock may not be as anticipated.
• If the Merger is consummated, our stockholders will not be able to participate in any further upside to the portion of our business acquired by Novartis.
• Risks Related to Our Limited Operating History, Financial Position and Capital Requirements
• We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any product revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.

Legal proceedings

We are not currently subject to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

The opening of Item 3, Legal Proceedings.¹¹